Radius Health, Inc. (RDUS): Price and Financial Metrics
GET POWR RATINGS... FREE!
RDUS Stock Price Chart Interactive Chart >
RDUS Price/Volume Stats
| Current price | $10.08 | 52-week high | $23.00 |
| Prev. close | $10.10 | 52-week low | $4.97 |
| Day low | $10.06 | Volume | 6,485,400 |
| Day high | $10.18 | Avg. volume | 1,172,199 |
| 50-day MA | $9.44 | Dividend yield | N/A |
| 200-day MA | $9.46 | Market Cap | 480.01M |
Radius Health, Inc. (RDUS) Company Bio
Radius Health is a biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. The company was founded in 2003 and is based in Waltham, Massachusetts.
Latest RDUS News From Around the Web
Below are the latest news stories about RADIUS HEALTH INC that investors may wish to consider to help them evaluate RDUS as an investment opportunity.
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of po |
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast CancerThe Menarini Group ("Menarini"), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review |
Mass. M&A activity picks up among life sciences firmsMergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come. |
Dave & Busters Entertainment and USA Truck Stock See Action From Activist InvestorsHill Path Capital disclosed a large stake in dining-and-entertainment firm Dave & Buster’s, and Magnetar Capital reported a 6% stake in logistics firm USA Truck. |
Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius HealthALPHARETTA, Ga., July 11, 2022--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, "Velan-Repertoire" or "we"), collectively one of the largest stockholders of Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today released the following statement: |
RDUS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 16.26% |
| 3-year | -18.58% |
| 5-year | -70.18% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -61.25% |
| 2020 | -11.41% |
| 2019 | 22.26% |
| 2018 | -48.10% |
Continue Researching RDUS
Want to see what other sources are saying about Radius Health Inc's financials and stock price? Try the links below:Radius Health Inc (RDUS) Stock Price | Nasdaq
Radius Health Inc (RDUS) Stock Quote, History and News - Yahoo Finance
Radius Health Inc (RDUS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...